STAT+: At MAHA Summit, a grassroots movement goes corporate
Federal officials and health care executives rubbed elbows at the ritzy MAHA Summit, causing some supporters to question what MAHA has become.
AstraZeneca has committed $2 billion towards Summit Therapeutics, according to recent reports. The sum represents the total potential value of the deal, should all future milestones be met. This investment comes after Novo Nordisk licensed a promising drug from Hengrui Pharma. The drug is a weekly oral medication combining GLP-1 and GIP receptor agonists, currently in Phase 1 clinical development. The deal price was $300 million upfront from Hengrui, excluding China.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
